Company Description
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. Sam Lee Ph.D. |
Contact Details
Address: 19805 North Creek Parkway Bothell, Washington 98011 United States | |
| Phone | 877 262 7123 |
| Website | cocrystalpharma.com |
Stock Details
| Ticker Symbol | COCP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001412486 |
| CUSIP Number | 19188J300 |
| ISIN Number | US19188J4094 |
| Employer ID | 35-2528215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James J. Martin CPA, M.B.A. | Co-Chief Executive Officer, Chief Financial Officer and Corporate Secretary |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-Chief Executive Officer and President |
| Prof. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | 10-Q | Quarterly Report |
| May 1, 2026 | EFFECT | Notice of Effectiveness |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 23, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 13, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |